

# G rard DE POUVOURVILLE

Emeritus Professor

Department: Economics  
ESSEC Business School  
3 avenue Bernard Hirsch  
95021 Cergy-Pontoise  
France

Email: gdepouvourville@free.fr  
Phone number: +33 (0)1 34 43 30 10  
Country of origin: France

## RESEARCH INTERESTS

---

Health Economics, health policy, hospital management

## EDUCATION

---

- |      |   |
|------|---|
| 1978 | Doctorate in Economics and Business Administration, Aix-Marseille University, France    |
| 1974 | Dipl me d'Etudes Sup rieures in Economics, Universit  Paris 1 Panth on-Sorbonne, France |
| 1970 | Graduate,  cole Polytechnique, France   |

## EMPLOYMENT

---

### Full-time academic positions

- |                |   |
|----------------|---|
| 2019 - Present | Emeritus Professor, ESSEC Business School, France |
| 2007 - 2019    | Professor, ESSEC Business School, France          |

### Other affiliations and appointments

- |             |   |
|-------------|---|
| 2006 - 2006 | Research teams manager, CERMES, INSERM U750, CNRS UMR 8169, Institut national de la sant  et de la recherche m dicale (INSERM), France  |
| 2004 - 2006 | Lecturer, Module « Pr paration   la vie professionnelle », DCEM2, Facult  de M decine de Bic tre, University Paris-Saclay, France   |
| 2003 - 2006 | Head of the Research Program « Epid miologie, Sant  Publique, Economie de la Sant  et Sciences Humaines et Sociales », at the Direction de la Recherche, Gustave Roussy, France                                 |
| 2000 - 2006 | Supervisor of Economics and Management courses, Master Sant  Publique, M1, University Paris-Saclay, France  |
| 2000 - 2006 | Track Head, "Economie de la Sant ", Master 2 Sant  Publique. Teaching and Dissertation mentoring, University Paris-Saclay, France   |
| 2000 - 2006 | Lecturer, with Monique Kerleau, "Approche  conomique et th orie des organisations appliqu es au syst me de soins", DESS Economie et Gestion des syst mes de sant , Universit  Paris 1 Panth on-Sorbonne, France |
| 2000 - 2006 | Head of the Etudes M dico-Economiques, part-time role, Gustave Roussy, France   |

- 2000 - 2005 Head of the Centre de Recherche en Economie et Gestion Appliquées à la Santé, INSERM U537, CNRS UMR 8052., Institut national de la santé et de la recherche médicale (INSERM), France
- 1998 - 2001 Associate Professor, Université de Lausanne, HEC Lausanne, Switzerland
- 1994 - 1999 Lecturer, Faculté de Médecine Saint-Louis-Lariboisière; teacher for the DEA "Système de soins hospitaliers et Société" (Director: Dominique Bertrand). Seminar "Evaluation des coûts à l'hôpital", seminar (with Alain Fontaine) "Préparation du mémoire de DEA"., Université Paris Cité, France
- 1993 - 2000 Scientific Director of Groupe Information Médicale et Aide à la Gestion des Etablissements (IMAGE); by the CNRS., École Nationale de la Santé Publique, France
- 1989 - 1993 Research Director, 2nd class, Centre de Recherche en Gestion, École Polytechnique, France
- 1989 - 1992 Research fellow, Groupe IMAGE, École Nationale de la Santé Publique, France
- 1986 - 1993 Lecturer; DEA 103 "Méthodes Scientifiques de Gestion" (Professor Bernard Roy), Paris-Dauphine, PSL University, France
- 1986 - 1986 Invited Researcher at Groupe de Recherche Interdisciplinaires en Santé (GRIS). Expert invited at the Commission d'Enquête sur les Services Sociaux et de Santé, Gouvernement du Québec., University of Montreal, Canada
- 1984 - 1984 Guest Researcher, Leonard Davis Institute for Health Economics, University of Pennsylvania, United States of America
- 1981 - 1989 Research fellow, CNRS, Centre de Recherche en Gestion, École Polytechnique, France
- 1979 - 1980 Part-time lecturer, Institut Auguste Comte pour l'Etude des Sciences de l'Action., École Polytechnique, France
- 1978 - 1981 Researcher, Centre de Recherche en Gestion, École Polytechnique, France
- 1976 - 1977 Economics classes lecturer, École Nationale du Génie Rural et des Eaux et Forêts (ENGREF), France
- 1973 - 1978 Doctorate, Centre de Recherche en Gestion, École Polytechnique, France
- 1973 - 1977 Economics class lecturer. In charge of the organization of final internships in Economics and Management., École Polytechnique, France

## PUBLICATIONS

---

### Journal Articles

THIEBLEMONT, C., COLRAT, F., SELLAMI, R., SIVIGNON, M., PETEL, A., BRANCHOUX, S. and DE POUVOURVILLE, G. (2026). CostEffectiveness Analysis of SecondLine Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large BCell Lymphoma. *European Journal of Haematology*.

GUERCI, B., BLANCBISSON, C., VICAUT, E., DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. ... RIVELINE, J. (2026). Economic burden of type 2 diabetes management in France according to clinical characteristics. *Diabetes, Obesity and Metabolism*, 28(5), pp. 4019-4032.

- LACAILLE, F., MARGUET, S., RASCON VELASCO, V., HASANOVA, R., AMRI, E., CHEVROU-SEVERAC, H. ... FEILLET, F. (2026). Real-World Study of Management and Outcomes of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) in France. *Advances in Therapy*, 43(5), pp. 2268-2282.
- MINVIELLE, E., LELEU, H., MASSETI, M., FERREIRA, A., PUYOU DE POUVOURVILLE, G., PALMA, M.D. and SCOTTÉ, F. (2025). A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial. *European Journal of Health Economics*, 26(2), pp. 267-273.
- CHOUAID, C., MARCHAL, C., APERT, M., BENSIMON, L., GUIMARD, V., NÉE, M. ... BLAY, J.Y. (2025). Epidemiology of metastatic lung cancer in France between 2013 and 2021: Observational study using the French claims database. *Bulletin du Cancer*, 112(2), pp. 166-177.
- AJJAN, R.A., BATTELINO, T., SEUFERT, J., BLIN, P., DE POUVOURVILLE, G., VICAUT, E. ... JOUBERT, M. (2025). Do continuous glucose monitoring (CGM) metrics predict macrovascular and microvascular complications in diabetes? The FACULTY protocol of a retrospective real-world cohort study. *BMJ Open*, 15(1), pp. e085961.
- MURPHY, L.A., AKEHURST, R., CUNNINGHAM, D., DE POUVOURVILLE, G. and SOLÀ-MORALES, O. (2025). Real-world evidence to support health technology assessment and payer decision making: is it now or never? *International Journal of Technology Assessment in Health Care*, 41(1), pp. e20, 1-7.
- BAILEY, M.D., FARGE, G., MOHANTY, S., BREAU-BRUNEL, M., ROY, G., DE POUVOURVILLE, G. ... JOHNSON, K.D. (2025). Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study. *Human Vaccines & Immunotherapeutics*, 21(1), pp. 2515760.
- CHOUAID, C., MARCHAL, C., APERT, M., BENSIMON, L., GUIMARD, V., NÉE, M. ... BLAY, J.Y. (2025). Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system. *European Journal of Health Economics*, In press.
- DE POUVOURVILLE, G. (2025). L'évolution de la place de l'évaluation économique en santé en France. *médecine/sciences*, 41, pp. 119-132.
- HANON, O., COHEN, A., JOURDAIN, P., LERAY, E., DE POUVOURVILLE, G., GOGUILLOT, M. ... LOGEART, D. (2025). Real-world persistence with sacubitril/valsartan in patients with heart failure in France: A claims database study. *Archives of Cardiovascular Diseases*, In press.
- CORCIA, P., STENSON, K., DOUTRIAUX, A., HADJRABIA, H., BOER, F., ISSA, S. ... COURATIER, P. (2025). Epidemiology, disease evolution and economic burden of amyotrophic lateral sclerosis in France using the French national health data system. *Brain Communications*, 7(4), pp. fcac292.
- SALORT-CAMPANA, E., LAFORET, P., PUYOU DE POUVOURVILLE, G., CROCHARD, A., CHOLLET, G., NEVORET, C. ... TARD, C. (2024). Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA). *Revue Neurologique*, 180(3), pp. 202-210.
- LOUBET, P., FERNANDES, J., PUYOU DE POUVOURVILLE, G., SOSNOWIEZ, K., ELONG, A., GUILMET, C. ... CHAKRA, C.N.A. (2024). Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study. *Journal of Clinical Virology*, 171, pp. 105635.
- VIGUIER, M., BENTAYEB, M., AZZI, J., PUYOU DE POUVOURVILLE, G., GLOEDE, T., LANGELLIER, B. ... BACHELEZ, H. (2024). Generalized pustular psoriasis: A nationwide populationbased study using the National Health Data System in France. *Journal of the European Academy of Dermatology and Venereology*, 38(6), pp. 1131-1139.

SZAFRANSKI, K., PUYOU DE POUVOURVILLE, G., GREENBERG, D., HARRIS, S., JENDLE, J., SHAW, J.E. ... LEVRAT-GUILLEN, F. (2024). The Determination of Diabetes Utilities, Costs, and Effects Model, A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation. *Value in Health*, 27(4), pp. 500-507.

PUYOU DE POUVOURVILLE, G. (2024). Les cellules CAR-T : prix, efficacité et soutenabilité en France. *Bulletin de l'Académie Nationale de Médecine*, 208(5), pp. 590-601.

PUYOU DE POUVOURVILLE, G., BREAU-BRUNEL, M., LONCLE-PROVOT, V., BECK, E., GAUGAIN, L., NACHBAUR, G. and PRIBIL, C. (2024). Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France. *PharmacoEconomics - Open*, 8(4), pp. 539-557.

PUYOU DE POUVOURVILLE, G., GUYOT, E., FARGE, G., BELHASSEN, M., BÉRARD, M., JACOUD, F. ... BALDAUF, J.J. (2024). Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study. *Vaccine*, 17(42), pp. 126039.

RIVELINE, J.P., LEVRAT-GUILLEN, F., DETOURNAY, B., VICAUT, E., PUYOU DE POUVOURVILLE, G., EMERY, C. and GUERCI, B. (2024). Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre® System Initiation in Some People With Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy Without Insulin in France. *Diabetes Technology & Therapeutics*, 26(12), pp. 932-938.

LARGERON, N., D'AGOSTINO, P., CHAPMAN, R., DANKO, D., ESKOLA, J., GODFROID, P. ... BECK, E. (2024). Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union's Regulation on Health Technology Assessment for Vaccines. *Value in Health*, 27(10), pp. 1318-1327.

CHOQUET, S., MARCHAL, C., DEYGAS, F., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G. and LEVY, V. (2024). A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS). *Annals of Hematology*, 103(8), pp. 2969-2981.

TARD, C., LAFORET, P., DE POUVOURVILLE, G., CROCHARD, A., CHOLLET, G., NEVORET, C. ... SALORT-CAMPANA, E. (2024). Treatment of myasthenia gravis in France: A retrospective claims database study (STAMINA). *Journal of Neurology*, 271(11), pp. 7239-7249.

GUERCI, B., ROUSSEL, R., LEVRAT-GUILLEN, F., DETOURNAY, B., VICAUT, E., PUYOU DE POUVOURVILLE, G. ... RIVELINE, J.P. (2023). Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France. *Diabetes Technology & Therapeutics*, 25(1), pp. 1-30.

GAUTIER, L., AZZI, J., SABA, G., BONNELLYE, G. and PUYOU DE POUVOURVILLE, G. (2023). Population norms in France with EQ-5D-5L: health states, value indexes, and VAS. *European Journal of Health Economics*, 24(9), pp. 1517-1530.

PUYOU DE POUVOURVILLE, G., ARMOIRY, X., LAVOREL, A., BILBAULT, P., MAUGENDRE, P., BENSIMON, L. ... VIPREY, M. (2023). Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials? *Therapies*, 78(1), pp. 81-94.

PUYOU DE POUVOURVILLE, G., CUNNINGHAM, D., FRICKE, F.U., LINDGREN, P. and MANTOVANI, L. (2023). Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. *Value in Health*, 26(4), pp. 11-19.

WANG, W., KOTHARI, S., KHOURY, H., NICCOLAI, L., GARLAND, S.M., SUNDSTRÖM, K. ... FRANCO, E.L. (2023). A review of data systems for assessing the impact of HPV vaccination in selected high-income countries. *Expert Review of Vaccines*, 22(1), pp. 161-179.

HENSHALL, C.H., DANKÓ, D., BARHAM, L., ESPÍN, J., FELIX, J., HARNEY, M. ... WILKING, N. (2023). Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe. *Applied Health Economics and Policy*, 21(4), pp. 537-546.

SOLÀ-MORALES, O., SIGURÐARDÓTTIR, K., AKEHURST, R., MURPHY, L.A., MESTRE-FERRANDIZ, J., CUNNINGHAM, D. and PUYOU DE POUVOURVILLE, G. (2023). Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. *Value in Health*, 26(4), pp. 32-42.

DRUMMOND, M., CIANI, O., FORNARO, G., JOMMI, C., DIETRICH, E.S., ESPIN, J. ... PUYOU DE POUVOURVILLE, G. (2023). How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? *BMC Health Services Research*, 23(484).

GUERCI, B., LEVRAT-GUILLEN, F., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. and RIVELINE, J.P. (2023). Reduced Acute Diabetes Events After FreeStyle Libre System Initiation in People 65 Years or Older with Type 2 Diabetes on Intensive Insulin Therapy in France. *Diabetes Technology & Therapeutics*, 25(6), pp. 384-394.

AKEHURST, R., MURPHY, L.A., SOLÀ-MORALES, O., CUNNINGHAM, D., MESTRE-FERRANDIZ, J. and PUYOU DE POUVOURVILLE, G. (2023). Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward. *Value in Health*, 26(4), pp. 11-19.

MURPHY, L.A., AKEHURST, R., SOLÀ-MORALES, O., CUNNINGHAM, D., MESTRE-FERRANDIZ, J., FRANKLIN, M. and PUYOU DE POUVOURVILLE, G. (2023). Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers. *Value in Health*, 26(4), pp. 20-31.

PUYOU DE POUVOURVILLE, G., ROSSIGNOL, P., BOUSSAHOVA, M., CHEVALIER, J., GABB, P.D., POULNAIS, R. ... GARCIA SANCHEZ, J.J. (2023). Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective. *Advances in Therapy*, 40, pp. 3751-3769.

SMITH, A., HANBURY, A., WHITTY, J., BEITIA ORTIZ DE ZARATE, I., PUYOU DE POUVOURVILLE, G., HAMMES, F. and BUESCH, K. (2022). A Discrete Choice Experiment to Derive Health Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in France. *Patient Related Outcome Measures*, (13), pp. 21-30.

THURIN, N., ROUYER, M., JOVÉ, J., GROSS-GOUPIL, M., HAASER, T., REBILLARD, X. ... BLIN, P. (2022). Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database. *Expert Review of Clinical Pharmacology*, 15(9), pp. 1139-1145.

WITHALL, A., JOMMI, C., PUYOU DE POUVOURVILLE, G., TAYLOR, D., ANNEMANS, L., SCHOONAERT, L. ... PATRIS, J. (2022). Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. *International Journal of Technology Assessment in Health Care*, 38(1), pp. e23, 1-8.

GILARD, M., ELTCHANINOFF, H., IUNG, B., LEFÈVRE, T., SPAULDING, C., DUMONTEIL, N. ... SHORE, J. (2022). Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France. *Value in Health*, 25(4), pp. 605-613.

- RIVELINE, J.P., ROUSSEL, R., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. ... GUERCI, B. (2022). Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. *Diabetes Technology & Therapeutics*, 24(9), pp. 611-618.
- ALLANORE, Y., CONSTANS, J., GODARD, D., PUYOU DE POUVOURVILLE, G., BOUEE, S., JEANBAT, V. ... HACHULLA, E. (2022). Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. *Journal of Scleroderma and Related Disorders*, 7(1), pp. 49-56.
- DALON, F., MAJED, L., BELHASSEN, M., JACOUD, F., BÉRARD, M., LÉVY-BACHELOT, L. ... BALDAUF, J.J. (2021). Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study. *Vaccine*, 39(36), pp. 5129-5137.
- DALON, F., MAJED, L., BELHASSEN, M., JACOUD, F., BÉRARD, M., LÉVY-BACHELOT, L. ... BALDAUF, J.J. (2021). Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study. *Vaccine*, 39(36), pp. 5129-5137.
- SMITH, A.B., HANBURY, A., BEITIA ORTIZ DE ZARATE, I., HAMMES, F., PUYOU DE POUVOURVILLE, G. and BUESCH, K. (2021). Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France. *Patient Related Outcome Measures*, 12, pp. 237-246.
- ROUSSEL, R., RIVELINE, J.P., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. ... GUERCI, B. (2021). Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. *Diabetes Care*, 44(6), pp. 1368-1376.
- RICHARD, M., PAUL, C., PUYOU DE POUVOURVILLE, G., JULLIEN, D., MAHE, E., BACHELEZ, H. ... EZZEDINE, K. (2021). Outofpocket expenditures in France to manage psoriasis in adult patients: results from an observational, crosssectional, noncomparative, multicentre study. *Journal of the European Academy of Dermatology and Venereology*, 35(4), pp. 912-918.
- PUYOU DE POUVOURVILLE, G. (2021). Logique médicale, économique, industrielle et politique dans la définition du « prix » du médicament. *Revue d'Économie Financière*, 2021/3(143), pp. 213-229.
- MISERY, L., SHOURICK, J., SÉNÉSCHAL, J., PAUL, C., PUYOU DE POUVOURVILLE, G., JULLIEN, D. ... RICHARD, M.A. (2021). Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients. *American Journal of Clinical Dermatology*, 22(2), pp. 285-287.
- JULLIEN, D., PAUL, C., SHOURICK, J., SÉNÉSCHAL, J., PUYOU DE POUVOURVILLE, G., MISERY, L. ... RICHARD, M.A. (2021). Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients. *Journal of the European Academy of Dermatology and Venereology*, 35(4), pp. e301-e303.
- DE POUVOURVILLE, G., BLIN, P. and KARAM, P. (2020). The Contribution of Real-World Evidence to Cost-Effectiveness Analysis: Case Study of Dabigatran Etxilate in France. *European Journal of Health Economics*, 21, pp. 235-249.
- ANDRADE, L.F., LUDWIG, K., RAMOS GONI, J.M., OPPE, M. and DE POUVOURVILLE, G. (2020). A French Value Set for the EQ5D5L. *Pharmacoeconomics*, 38(1), pp. 1-13.
- TÉHARD, B., DETOURNAY, B., BORGET, I., ROZE, S. and PUYOU DE POUVOURVILLE, G. (2020). Value of a QALY for France: A New Approach to Propose Acceptable Reference Values. *Value in Health*, 23(8), pp. 985-993.

- QUINN, C., GARRISON, L.P., POWNELL, A.K., ATKINS, M.B., PUYOU DE POUVOURVILLE, G., HARRINGTON, K. ... WU, E. (2020). Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. *Journal for ImmunoTherapy of Cancer*, 8(2), pp. e000648.
- GOODALL, G., LAMOTTE, M., RAMOS, M., MAUNOURY, F., PEJCHALOVA, B. and DE POUVOURVILLE, G. (2019). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. *Journal of Medical Economics*, 22(4), pp. 289-296.
- CHOUAID, C., GERMAIN, N., PUYOU DE POUVOURVILLE, G., ABALLEA, S., KORCHAGINA, D. and BALDWIN, M. (2019). Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. *Current Medical Research and Opinion*, 35(5), pp. 785-792.
- DE POUVOURVILLE, G. and KARAM, P. (2019). Le coût hospitalier des événements cérébro-vasculaires associés à une fibrillation atriale en France. *Journal de Gestion et d'Économie de la Santé*, 37(5), pp. 399-409.
- ANDRADE, L.F., SABA, G., RICARD, J.D., MESSIKA, J., GAILLAT, J., BONNIN, P. ... PUYOU DE POUVOURVILLE, G. (2018). Health related quality of life in patients with community-acquired pneumococcal pneumonia in France. *Health and Quality of Life Outcomes*, 16(1).
- PUYOU DE POUVOURVILLE, G. (2016). Anticoagulants d'action directe: une revue de la littérature des études coût/efficacité en Europe. *Archives of Cardiovascular Diseases Supplements*, 8(2), pp. 180-191.
- PERSONNE, V., CHEVALIER, J., BUFFEL DU VAURE, C., PARTOUCHE, H., GILBERG, S. and DE POUVOURVILLE, G. (2016). CAPECO: Cost Evaluation of Community Acquired Pneumonia Managed in Primary Care. *Vaccine*, 19(34), pp. 2275-2280.
- PUYOU DE POUVOURVILLE, G. (2016). Comment Améliorer le Suivi des AVK et pour quel Coût? *Archives of Cardiovascular Diseases Supplements*, 8(2), pp. 169-173.
- PUYOU DE POUVOURVILLE, G. (2016). Coût de la Prise en Charge des Accidents Vasculaires Cérébraux en France. *Archives of Cardiovascular Diseases Supplements*, 8(2), pp. 161-168.
- PUYOU DE POUVOURVILLE, G. (2016). La Tarification à l'Activité est-elle Compatible avec les Valeurs des Professionnels de Santé ? *Médecine de l'Homme*, (15), pp. 11-25.
- PUYOU DE POUVOURVILLE, G. (2016). Quel prix payer pour un bénéfice en santé ? *SEP et Neurosciences*, (5), pp. 4-11.
- COHEN, A. and PUYOU DE POUVOURVILLE, G. (2016). Rapport coût/efficacité des traitements médicamenteux et interventionnels dans la fibrillation atriale. *Archives of Cardiovascular Diseases Supplements*, 8(2), pp. 141-143.
- BELHASSEN, M., DE BLIC, J., LAFOREST, L., LAIGLE, V., CHANUT-VOGEL, C. and DE POUVOURVILLE, G. (2016). Recurrent Wheezing in Infants. *Medicine*, 95(15).
- BELHASSEN, M., PUYOU DE POUVOURVILLE, G., LAFOREST, L., BROUARD, J., DE BLIC, J., FAUROUX, B. ... VAN GANSE, E. (2015). Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study. *BMC Pulmonary Medicine*, 15(Art. 51).
- DRUMMOND, M., PUYOU DE POUVOURVILLE, G., JONES, E., HAIG, J., SABA, G. and CAWSTON, H. (2014). A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France. *Pharmacoeconomics*, 32(5), pp. 509-520.

- BONASTRE, J., CHEVALIER, J., VAN DER LAANC, C., DELIBESC, M. and PUYOU DE POUVOURVILLE, G. (2014). Access to Innovation: Is there a Difference in the Use of Expensive Anticancer Drugs Between French Hospitals? *Health Policy*, 116(2&3), pp. 162-169.
- PUYOU DE POUVOURVILLE, G. (2013). Editorial: HAS to be NICE? *European Journal of Health Economics*, 14, pp. 363-366.
- PUYOU DE POUVOURVILLE, G. (2013). Editorial: Paying Doctors for Performance. *European Journal of Health Economics*, 14(1), pp. 1-4.
- CHEVALIER, J., GIROUD, M. and PUYOU DE POUVOURVILLE, G. (2013). Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation. *Cerebrovascular Diseases*, 35(4), pp. 320-326.
- RENARD, J.P., ROULAND, J.F., BRON, A., SELLEM, E., NORDMANN, J.P. and DE POUVOURVILLE, G. (2013). Nutritional, Lifestyle and Environmental Factors in Ocular Hypertension and Primary Open-Angle Glaucoma: An Exploratory Case-Control Study. *Acta Ophthalmologica*, 61(6), pp. 505-513.
- GARRISON, L.P., TOWSE, A., BRIGGS, A., PUYOU DE POUVOURVILLE, G., GRUEGER, J. and MOHR, P.E. (2013). Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. *Value in Health*, 16(5), pp. 703-719.
- DERVAUX, B., BASEILHAC, E., FAGON, J.Y., AMEYE, V., ANGOT, P., AUDRY, A. ... SUN, A. (2013). Medico-economic Evaluation of Health Products in the Context of the Social Security Financing Act for 2012. *Therapies*, 68(4), pp. 259-263.
- LUPORSI, E., MAHI, L., MORRE, C., WERNLI, J., PUYOU DE POUVOURVILLE, G. and BUGAT, R. (2012). Evaluation of Cost Savings with Ferric Carboxymaltose in Anemia Treatment Through Its Impact on Erythropoiesis-Stimulating Agents and Blood Transfusion: French Healthcare Payer Perspective. *Journal of Medical Economics*, 15(2), pp. 225-232.
- SMOLDEREN, K.G., WANG, K., PUYOU DE POUVOURVILLE, G., BRÜGGENJÜRGEN, B., RÖTHER, J. and ZEYMER, U. (2012). Two-Year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease. *European Journal of Vascular and Endovascular Surgery*, 43(2), pp. 198-207.
- PUYOU DE POUVOURVILLE, G., ULMANN, P., NIXON, J., BOULENGER, S., GLANVILLE, J. and DRUMMOND, M. (2012). The Diffusion of Health Economics Knowledge in Europe. *Pharmacoeconomics*, 23(2), pp. 113-120.
- COTTE, F.E. and PUYOU DE POUVOURVILLE, G. (2011). Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France. *BMC Health Services Research*, 151(11), pp. 1-10.
- PUYOU DE POUVOURVILLE, G. (2011). L'assurance maladie en France: Beveridge et Bismarck enfin reconciliés? *Réalités Industrielles (série des "Annales des Mines")*, pp. 19-24.
- COHEN, S.Y., SOUIED, E.H., WEBER, A.P., DUPEYRON, G., PUYOU DE POUVOURVILLE, G. and LIEVRE, M. (2011). Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 249(4), pp. 521-527.
- BONASTRE, J., LE VAILLANT, M. and PUYOU DE POUVOURVILLE, G. (2011). The Impact of Research on Hospital Costs of Care: An Empirical Study. *Health Economics*, 20(1), pp. 73-84.

- CHEVALIER, J. and PUYOU DE POUVOURVILLE, G. (2011). Valuing EQ-5D using Time Trade-Off in France. *European Journal of Health Economics*, 14(1), pp. 57-66.
- PUYOU DE POUVOURVILLE, G. (2010). Editorial: A French Approach to Cost-Effectiveness Analysis? *European Journal of Health Economics*, 11(6), pp. 521-523.
- CARO, J.J., NORD, E., MCGUIRE, A., MCGREGOR, D.H., PUYOU DE POUVOURVILLE, G. and ATELLA, V. (2010). IQWiG Methods – A Response to Two Critiques. *Health Economics*, 19(10), pp. 1137-1138.
- PUYOU DE POUVOURVILLE, G. (2010). La crise d'identité des médecins face au nouveau management de l'hôpital. *Journal de l'Ecole de Paris du Management*, 6(86), pp. 22-29.
- CARO, J.J., NORD, E., SIEBERT, U., MCGUIRE, A., MCGREGOR, M. and DE POUVOURVILLE, G. (2010). The Efficiency Frontier Approach to Economic Evaluation of Health-Care Interventions. *Health Economics*, 19(10), pp. 1117-1127.
- COTTE, F.E., FAUTREL, B. and PUYOU DE POUVOURVILLE, G. (2009). A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis. *Medical Decision Making*, 29(1), pp. 125-139.
- CLERC, P., LE BRETON, J., MOUSQUES, J., HEBBRECHT, G. and PUYOU DE POUVOURVILLE, G. (2009). Etude polychrome : une méthode d'expertise pour optimiser des vignettes de polyprescription en médecine générale. *Pratiques et Organisation des Soins*, 40(3), pp. 165-174.
- PUYOU DE POUVOURVILLE, G. (2009). Exploitation seconde de la base de l'Etude nationale de coûts (ENC). *Dossiers Solidarité et santé*, (9), pp. 2-6.
- NIXON, J., RICE, S., DRUMMOND, M., BOULENGER, S., ULMANN, P. and DE POUVOURVILLE, G. (2009). Guidelines for Completing the EURONHEED Transferability Information Checklists. *European Journal of Health Economics*, 10(2), pp. 157-165.
- PUYOU DE POUVOURVILLE, G. (2009). Les hôpitaux français face au paiement prospectif au cas. La mise en œuvre de la tarification à l'activité. *Revue Economique*, 60(2), pp. 457-470.
- TIBI-LEVY, Y. and PUYOU DE POUVOURVILLE, G. (2009). Qu'est-ce qu'une unité de soins "performante", du point de vue des malades relevant de soins palliatifs et de leurs proches ? *Médecine palliative*, 8(2), pp. 53-65.
- DEJARDIN, O., BOUVIER, A.M., FAIVRE, J., BOUTREUX, S., PUYOU DE POUVOURVILLE, G. and LAUNOY, G. (2008). Access to Care, Socioeconomic Deprivation and Colon Cancer Survival. *Alimentary Pharmacology & Therapeutics*, 27(10), pp. 940-949.
- BORGET, I., VIELH, P., LEBoulLEUX, S., ALLYN, M., IACOBELLI, S. and DE POUVOURVILLE, G. (2008). Assessment of the Cost of Fine-needle Aspiration Cytology as a Diagnostic Tool in Patients with Thyroid Nodules. *American Journal of Clinical Pathology*, 129(5), pp. 763-771.
- PUYOU DE POUVOURVILLE, G., SOLESSE, A. and BEILLAT, M. (2008). Cost-effectiveness Analysis of Aldosterone Blockade with Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction in the French Context: The EPHEBUS Study. *Archives of Cardiovascular Diseases*, 101(9), pp. 515-521.
- BONASTRE, J., CHEVALIER, J., ELIAS, D., CLASSE, J.M., FERRON, G. and DE POUVOURVILLE, G. (2008). Cost-effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer. *Value in Health*, 11(3), pp. 347-353.

- CLERC, P., LEBRETON, J., MOUSQUES, J., HEBBRECHT, G. and PUYOU DE POUVOURVILLE, G. (2008). Etude polychrome : construction d'une typologie des pathologies chroniques en médecine générale, pour une analyse de la poly-prescription. *Pratiques et Organisation des Soins*, 39(1), pp. 43-51.
- BORGET, I., REMY, H., CHEVALIER, J., RICARD, M., ALLYN, M. and DE POUVOURVILLE, G. (2008). Length and Cost of Hospital Stay of Radioiodine Ablation in Thyroid Cancer Patients: Comparison between Preparation with Thyroid Hormone Withdrawal and Thyrogen. *European Journal of Nuclear Medicine and Molecular Imaging*, 35(8), pp. 1457-1463.
- COTTE, F.E., MERCIER, F. and PUYOU DE POUVOURVILLE, G. (2008). Relationship Between Compliance and Persistence with Osteoporosis Medications and Fracture Risk in Primary Health Care in France: A Retrospective Case-control Analysis. *Clinical Therapeutics*, 30(12), pp. 2410-2422.
- TIBI-LEVY, Y., PUYOU DE POUVOURVILLE, G., WESTERLOPPE, J. and BAMBERGER, M. (2008). The Cost of Treating High Blood Pressure in General Practice in France. *European Journal of Health Economics*, 9(3), pp. 229-236.
- PUYOU DE POUVOURVILLE, G. (2007). Editorial : La réforme de la gouvernance hospitalière : mission impossible? *La Presse Médicale*, 36(4), pp. 636-637.
- PUYOU DE POUVOURVILLE, G., BORGET, I. and SCHLUMBERGER, M. (2007). Health-related Quality of Life - An Economist's Perspective (Viewpoint). *Nature Reviews Endocrinology*, 3(12), pp. 2-3.
- SCHLUMBERGER, M., RICARD, M., PUYOU DE POUVOURVILLE, G. and PACINI, F. (2007). How the Availability of Recombinant Human TSH Has Changed the Management of Patients Who Have Thyroid Cancer. *Nature Reviews Endocrinology*, 3(9), pp. 641-650.
- PUYOU DE POUVOURVILLE, G. (2007). Qu'est-ce que la recherche en médecine générale ? *La Revue du Practicien*, 57(11), pp. 1181-1185.
- DE POUVOURVILLE, G., BORGET, I. and SCHLUMBERGER, M. (2007). Calcitonin determination in patients with nodular thyroid disease. *The Journal of Clinical Endocrinology & Metabolism*, 92(2), pp. 425-427.
- DE POUVOURVILLE, G., BONASTRE, J., DE BAÈRE, T., ELIAS, D. and SERGE, E. (2007). Cost of radiofrequency ablation in the treatment of hepatic malignancies. *Gastroentérologie Clinique et Biologique*, 31, pp. 828-835.
- DE POUVOURVILLE, G. and SPIELER, J.F. (2007). Evaluation du coût de la prise en charge ambulatoire des patients après AVC: résultats d'une enquête postale auprès des patients du registre des AVC de Dijon. *La Presse Médicale*, 36(3), pp. 399-403.
- DE POUVOURVILLE, G., HALLAIS, C., CZERNICHOW, P., LE VAILLANT, M. and FROMENT, L. (2007). Gravité des patients et surcoûts dans les hôpitaux de référence. *Journal d'Economie Médicale*, 25(3), pp. 177-187.
- DE POUVOURVILLE, G., BORGET, I. and SCHLUMBERGER, M. (2007). Health-related quality of life- an economist's perspective. *Nature Clinical Practice Endocrinology & Metabolism*, 3, pp. 786-787.
- DE POUVOURVILLE, G. and PRIOLLET, P. (2007). Impact du choix d'une thérapie anti-agrégante dans l'artériopathie des membres inférieurs: étude coût-efficacité et impact économique. *Journal des Maladies Vasculaires*, 32(1), pp. 8-14.

BONASTRE, J., CHEVALIER, J., GÉRARD, J.P., LEFKOPOULOS, D. and DE POUVOURVILLE, G. (2007). Implications of learning effects for hospital costs of new technologies: the case of intensity modulated radiation therapy. *International Journal of Technology Assessment in Health Care*, 23(2), pp. 248-254.

DE POUVOURVILLE, G. (2007). La recherche en médecine générale en France: état es lieux. *La Revue du Practicien*, 57(11), pp. 1200-1202.

DE POUVOURVILLE, G. (2007). Réformer la gouvernance de l'hôpital: mission impossible? *La Presse Médicale*, 36(4), pp. 636-637.

DE POUVOURVILLE, G., BORGET, I., CORONE, C., NOCAUDIE, M. and ALLYN, M. (2007). Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. *European Journal of Endocrinology*, 156(5), pp. 531-538.

DE POUVOURVILLE, G., TIBI-LÉVY, Y., BAMBERGER, M. and WESTTERLOPPE, J. (2007). The cost of treating high blood pressure in France. *European Journal of Health Economics*.

### Books and book editor

BRAS, P.L., PUYOU DE POUVOURVILLE, G. and TABUTEAU, D. [Eds] (2009). *Traité d'économie et de gestion de la santé*. Presses de Sciences Po, 564 pages.

KIMBERLY, J., PUYOU DE POUVOURVILLE, G. and D'AUNNO, T. [Eds] (2008). *The Globalization of Managerial Innovation in Health Care*. Cambridge University Press, 379 pages.

### Book chapters

PUYOU DE POUVOURVILLE, G. (2021). La fabrication du prix du médicament. In: Thomas Barnay, Anne-Laure Sanson, Bruno Ventelou eds. *Le système de santé français : aujourd'hui. Enjeux et défis*. 1st ed. ESKA.

PUYOU DE POUVOURVILLE, G. (2021). Trente ans de dépenses de santé en France. In: René Demeleumeester, Jean-Calude Henrard, Bernadette Roussille, Patricia Siwek eds. *Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?* 1st ed. Boulogne-Billancourt: Berger-Levrault, pp. 255-270.

PUYOU DE POUVOURVILLE, G. (2021). Trente ans d'administration et de financement du système de soins. In: René Demeleumeester, Jean-Calude-Henrard, Bernadette Roussille, Patricia Siwek eds. *Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?* 1st ed. Boulogne-Billancourt: Berger-Levrault, pp. 125-140.

PUYOU DE POUVOURVILLE, G., CONTI, C. and BIBAULT, E. (2009). La distribution du médicament en France. In: *Traité d'économie et de gestion de la santé*. 1st ed. Presses de Sciences Po, pp. 427-434.

PUYOU DE POUVOURVILLE, G. (2009). Le financement des hôpitaux. In: *Traité d'économie et de gestion de la santé*. 1st ed. Presses de Sciences Po, pp. 269-274.

PUYOU DE POUVOURVILLE, G. (2009). L'économie de la santé : périmètre et questions de recherche. In: *Traité d'économie et de gestion de la santé*. 1st ed. Presses de Sciences Po, pp. 15-24.

PUYOU DE POUVOURVILLE, G., BRAS, P.L. and TABUTEAU, D. (2009). L'industrie pharmaceutique en France. In: *Traité d'économie et de gestion de la santé*. 1st ed. Presses de Sciences Po, pp. 415-426.

PUYOU DE POUVOURVILLE, G. (2009). L'organisation des soins. In: *Traité d'économie et de gestion de la santé*. 1st ed. Presses de Sciences Po, pp. 401-406.

D'AUNNO, T., KIMBERLY, J. and PUYOU DE POUVOURVILLE, G. (2008). Conclusions: The Global Diffusion of Casemix. In: *The Globalization of Managerial Innovation in Health Care*. 1st ed. Cambridge University Press, pp. 346-372.

PUYOU DE POUVOURVILLE, G. (2007). Les conséquences économiques des droits des malades. In: *Les droits des malades et des usagers du système de santé, une législation plus tard*. 1st ed. Presses de Sciences Po, pp. 53-58.

### Conference proceedings editor

PUYOU DE POUVOURVILLE, G. (2009). 26th Scientific Plenary Meeting of the EuroQol Group. EuroQol Group, Netherlands.

### Conference proceedings

PUYOU DE POUVOURVILLE, G. (2016). Le territoire dans la régulation du système de santé. In: *Management hospitalier et territoire: les nouveaux défis*. Presses des Mines.

FEARON, W., BORNSCHEIN, B., ARVANDI, M., GOTHE, R., RIOUFOL, G., DE BRUYNE, B. ... SIEBERT, U. (2011). Cost-effectiveness of fractional flow reserve measurement in multivessel coronary artery disease in Belgium and in France. In: *ISPOR Europe*. Value in Health, pp. 251.

### Conferences

CHOQUET, S., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G., MARCHAL, C., BELHASSEN, M. ... LEVY, V. (2022). Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS). In: American Society of Hematology Conference.

COAQUIRA CASTRO, J., PUYOU DE POUVOURVILLE, G., GREENBERG, D., HARRIS, S., JENDLE, J., SHAW, J. ... SZAFRANSKI, K. (2022). P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes. In: ISPOR Europe 2022. Vienna & Virtual.

MOLNAR, A., STÖRZEL, M., MUCHADEYI, M., BAIRD, R., IMAZ-IGLESIA, I., NAGY, B. ... SCHLANDER, M. (2022). MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop. In: ISPOR Europe 2022. Vienna & Virtual.

SIGURÐARDÓTTIR, K., SOLA-MORALES, O., MURPHY, L., CORRY, S., MESTRE-FERRANDIZ, J., CUNNINGHAM, D. ... PUYOU DE POUVOURVILLE, G. (2022). POSB405 Data Governance for Rwd/E Management: Optimising Its Use in HTA and Decision-Making. In: Virtual ISPOR Europe 2021 Meeting.

### Press

PUYOU DE POUVOURVILLE, G. 2016. *La territorialisation aux mains des CPTS et des GHT*. December.

## OTHER RESEARCH ACTIVITIES

---

### Editorial Board Membership

2016 - 2018 Gérer et Comprendre

### Ad-hoc reviewer for :

European Journal of Health Economics, Gérer et Comprendre, Health Economics, International Journal of Technology Assessment in Health Care, Pharmacoeconomics, Politiques et Management Public, Revue Française de Gestion, Social Science and Medicine

### Organisation of a conference

1989 - 1998 Organization and co-organization of 8 symposia and research seminars, 3 of them as a member of the scientific committee of "mini-symposia" INSERM

### Affiliations

- 2002 - 2005 Designated member of the board of directors of INSERM
- 2001 - 2006 Member of the Comité Directeur of IFR "Epidémiologie, Santé Publique, Sciences Sociales"
- 2000 - 2005 President of the Collège des Economistes de la Santé, member of the Conseil d'Administration, hence scientific supervisor of the organization of two international symposia; promoter of the basis of the documentary « Connaissance et Décision en Economie de la Santé », creator of the European network (16 countries) of documentary databases in Health Economics "EURONHEED"; co-supervisor of the writing of « Recommandations pour l'évaluation économique des stratégies de santé », France
- 2000 - 2006 Coordinator of the Comité d'Interface INSERM/Médecine Générale
- 2000 - 2006 Member of the Comité Scientifique Sciences Humaines et Sociales, Institut National du Cancer.
- 1998 Member of the scientific evaluation mission of Agence Nationale de Recherche sur le SIDA, Ministère de la Recherche et de la Technologie.
- 1998 - 2000 Member of the Scientific Council of Institut Paoli Calmettes
- 1997 - 2000 Member of the Scientific Council of Institut Universitaire de Santé Publique of Ile de France
- 1996 - 1998 Scientific supervisor of the France-Québec scientific cooperation program "Economie de la Santé".
- 1995 - 1998 Member of the Scientific Council of Institut d'Etude des Politiques de Santé, Paris V.
- 1995 - 2000 Elected member of the Comité National, section 37 « Economie et Société »
- 1995 - 1999 Member of the Scientific Council of Ecole Nationale de la Santé Publique
- 1992 - 1994 Scientific Committee President of the invitation to tender "Evaluation Economique des Stratégies Préventives et Thérapeutiques", Ministère de la Recherche
- 1990 - 1995 Designated member of the Scientific Council of INSERM
- Since 1950 Member of the International Health Economics Association (IHEA)

### PhD Supervision

- 2020 (University Paris-Saclay), Thesis director
- 2019 (Université Paris Descartes (Paris V)), Thesis referee

2018 (University Paris-Saclay), Thesis referee

2017 J. BONASTRE (University Paris-Saclay), Thesis director

2016 (University Paris-Saclay), Thesis jury member

2016 (Université Paris Est Créteil), Thesis jury member

2016 (Paris-Dauphine, PSL University), Thesis jury member

2016 (Université de Bourgogne), Thesis referee

2016 (Université Lyon 2), Thesis jury member

2016 (Paris-Dauphine, PSL University), Thesis referee

2015 (Université Paris 1 Panthéon-Sorbonne), Thesis referee

2015 (Université Pierre et Marie Curie (UPMC)), Thesis referee

2014 (Paris-Dauphine, PSL University), Thesis referee

2013 (Paris-Dauphine, PSL University), Thesis referee

2012 (University Paris-Saclay), Thesis jury member

2012 (Université Paris 1 Panthéon-Sorbonne), Thesis jury president

2011 (Paris-Dauphine, PSL University), Thesis referee

2010 J. CHEVALIER (Paris-Dauphine, PSL University), Thesis director

2010 (Aix-Marseille University), Thesis referee

2010 (Paris-Dauphine, PSL University), Thesis referee

2010 (EHESS - École des hautes études en sciences sociales), Thesis referee

2009 (University Paris-Saclay), Thesis director

2009 O. DEJARDIN (University Paris-Saclay), Thesis director

2008 I. BORGET-VANDERVERREN (University Paris-Saclay), Thesis director

2008 (Université Pierre et Marie Curie (UPMC)), Thesis referee

2008 (Aix-Marseille University), Thesis referee

2007 (University Paris-Saclay), Thesis director

2007 (Paris-Dauphine, PSL University), Thesis director

2007 (University Paris-Saclay), Thesis co-director

2007 (University Paris-Saclay), Thesis director

2007	(University Paris-Saclay), Thesis director
2004	(University of Caen), Thesis jury member
2003	(Université Paris 1 Panthéon-Sorbonne), Thesis director
2003	(École Polytechnique), Thesis director
2003	(Université Paris-Diderot (Paris VII)), Thesis director
2003	(Université Paris-Diderot (Paris VII)), Thesis director
2002	(Université Paris-Diderot (Paris VII)), Thesis director
2001	(Université Paris-Diderot (Paris VII)), Thesis director
1999	(University Paris-Saclay), Thesis director
1999	(École Polytechnique), Thesis director, First Placement: Conseil en entreprise
1999	(Université Paris-Diderot (Paris VII)), Thesis director
1998	(École Polytechnique), Thesis director
1998	(Institut d'Etudes Politiques), Thesis jury member
1997	(Université Toulouse III Paul Sabatier), Thesis jury member
1997	(Université de Bourgogne), Thesis jury member
1996	(École Polytechnique), Thesis director
1995	(IUT Sceaux - Université Paris Sud), Thesis co-director
1994	(École Polytechnique), Thesis director, First Placement: Université de Grenoble
1994	(Aix-Marseille University), Thesis director
1992	(École Polytechnique), Thesis director
1992	(École Polytechnique), Thesis director, First Placement: INRA
1988	(École Polytechnique), Thesis director

### Other research activities

Since 1995	Member of the Scientific Council of l'Institut de Recherche et de Documentation en Economie de la Santé (IRDES), Caisse Nationale d'Assurance Maladie, France
Since 1950	Member of the Scientific Council of Mission Innovation, Recherche et Expérimentation (MIRE), DREES, Ministère de la Santé, France
Since 1950	Member of the Steering Committee on research operations of Haute Autorité de Santé, France

## TEACHING EXPERIENCE

---

2014	Msc in Management of Health Industries, ESSEC Business School, Singapour
2013	Hospital Management program, ESSEC Business School, France
2012	Health Technology assessment in Asia Pacific, ESSEC Business School, Singapour
2007	Health care Systems- Health product marketing, ESSEC Business School, France

## PROFESSIONAL ACTIVITIES

---

### Consulting

2004	Consultant for Centre Hospitalier de Lagny-Marne-la-Vallée: implementation of intern contractualization
2003	Expert for the Royal Commission for the reform of the Canadian Health System (Romanow Commission)
2001 - 2003	Vice-President of the Comité d'Orientation, Observatoire des Prescriptions et de la Consommation des Médicaments, Ministère de la Solidarité Nationale, de l'Emploi et de la Santé.
1983 - 1984	Consultant for Direction Générale de la Santé, Ministère de la Santé; expert for the Commission Nationale d'Anesthésiologie about specialty demography regulation.
1982 - 1996	Consultant for the Direction des Hôpitaux, Ministère de la Santé; conception of medical information systems for hospitals, in charge of the development of a budgetization method based on the medical activity of the establishments ; participation in the writing of Etude Nationale des Coûts.
1974	Consultant for OECD, on the project "Politiques pour l'innovation dans le secteur des services".
1950 - Present	Consultant for the laboratories: MSD, Sanofi-Aventis, Astra-Zeneca, Pfizer, Servier, Procter & Gamble, BMS, Bayer SA.
1950 - Present	Consultant, Centre Hospitalier Régional Universitaire de Lille, evaluation of the Missions d'Intérêt Général et d'Aide à la Contractualisation, as part of the Tarification à l'Activité., France
1950 - Present	For the Ministre de la Santé and the Ministre Délégué à la Recherche, about the development of general medicine research in France., France

### Other professional activities

2004	Member of the Comité d'Experts, Tarification à l'Activité, Ministère de la Santé
1992 - Present	Member of the Groupe de Prospective Santé 2010, Commissariat Général au Plan ; writer of the health system regulation regionalization scenario (Rapport Santé 2010, under the supervision of Raymond Soubie) ; to this end writer of a synthesis presenting a creation project of Health Regional Agencies.
1950 - Present	Invited Expert, Ministère de la Santé et du Bien-être, Province d'Alberta, Canada., Canada
1950 - Present	Scientific expert for the Mission Tarification à l'Activité, Ministère de la Santé- Participation in the working group on the topic : Financement des Missions d'Intérêt Général et d'Aide à la Contractualisation, France

1950 - Present Member of the Commission des Comptes de la Santé

1950 - Present Member of the Global Health Outcome Board, Groupe Glaxo-Smith-Kline